Loading...

Global Health IPO Review Summary

Review By Subscribe Neutral Avoid
Brokers 9 0 0
Members 7 3 3

Global Health IPO Details

IPO Open Nov 3, 2022
IPO Close Nov 7, 2022
IPO Price ₹336
Face Value ₹2
IPO Size ₹2,205.57 Cr
Listing At BSE, NSE
Lot Size 44

Global Health IPO Review by Brokers & Analysts

ReviewerRecommendation
Axis CapitalNot Rated
BP Equities (BP Wealth)Apply
Canara BankMay Apply
Capital MarketMay Apply
Choice Equity Broking Pvt LtdApply
Dilip DavdaApply
HDFC Securities LimitedNot Rated
Jainam Broking limitedMay Apply
Nirmal BangApply
Reliance SecuritiesApply
Sharekhan LimitedNot Rated
TopShareBrokers.comMay Apply

Global Health IPO Capital Market Rating

ReviewerRating
Capital Market45

Global Health IPO Review by Members

Global Health IPO Reviews, analysis and views by popular members. Read Global Health Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Clear Search
Member Review
Crow
Top Contributor Top Contributor (300+ Posts, 200+ Likes)

Subscribe for Listing Gain at Cut-off Price

Barring poor GMP (12), high OFS (1700 cr), and low post-IPO promoter holding (33), I see some potential in this hospital stock. Hospitals have been usually well-received by the markets, plus the decent subscription levels tell me this may be a good bet even for longterm. Taking the gamble. 5 red flags out of 13.

Nov 7, 2022 1:49:03 PM
MAMU
Top Contributor Top Contributor (400+ Posts, 300+ Likes)

Neutral

In waves of MAIN BOARD & SMES ipo, this will have a tough competition.
Listing gain may be surprising.

Nov 3, 2022 11:34:29 PM
Nomee

Subscribe for Listing Gain at Upper Price Band

This is THE Brand with reasonable valuation, Must subscribe.

Nov 3, 2022 7:07:29 PM
ramsita (200+ Posts)

Avoid

Uncertaintey

Nov 3, 2022 1:51:14 PM
B.M.SURANA
IPO Mentor IPO Mentor (700+ Posts, 700+ Likes)

Subscribe for Long Term at Cut-off Price

Fundamentally strong Company.
Brand Value
World ke Top 200 Hospitals Mein ek hai "Medanta"
KhelaHobe
खेला होबे
খেলা হবে

I Like It. 1

Nov 3, 2022 1:04:21 PM
XCapitalMarkets

Subscribe for Long Term at Cut-off Price

Great brand value, high-quality business, solid management. Growth path in place, and new hospitals ramping up fast. Valued at 18.5x FY22 EBITDA, whereas peers trade at average of 25x, so attractive pricing.

Nov 3, 2022 9:29:36 AM
Abhijeet Kumar

Avoid

Instead of applying in such poor quality IPO like Fusion and Global health its better to buy good quality scrips from secondary market which are trading at cheap valuations. Few of my suggestions to buy would be : Sanofi India, Johnson Control, Tamilnad Merchantile Bank, GE T&D India, Bector Foods, Railtel etc,

Nov 3, 2022 2:20:31 AM
AJS

Subscribe for Long Term at Upper Price Band

Available at reasonable valuations compared to Apollo, Fortis.

Nov 2, 2022 9:31:15 PM
Liger

Neutral

IPO pricing is at its fair value.
Good Brand.
Good for Long term.

I Like It. 1

Nov 2, 2022 3:59:20 PM
Top Contributor

Neutral

May Apply

Nov 1, 2022 9:26:35 AM
Immortal

Avoid

HUGE OFS ISSUE. NOT FAIRLY PRICED AND POST ISSUE HOLDING WILL JUST 33%.

Oct 30, 2022 10:02:44 PM
bansalVijay

Subscribe for Listing Gain at Upper Price Band

Many people are comparing it with max hospital and inferring Medanta costly but how. Max with 600 crores profit has market cap of 41000 crores while Medanta with 200 crores profit seems to have market cap of 8000 crores. Can anyone shed light on this.

Oct 30, 2022 10:39:44 AM
arunARUN
IPO Guru IPO Guru (1500+ Posts, 1400+ Likes)

Subscribe for Short Term at Cut-off Price

Attractively priced. Though share is good for long term also but in short term prices may run ahead of fundamentals

Oct 29, 2022 9:05:21 AM

Post Recommendation Manage Recommendations

Note:

  • The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
  • We reserve the right to remove any objectionable post without providing a reason.